Enjoy complimentary customisation on priority with our Enterprise License!
The liver cancer drugs market share is expected to increase by USD 5.29 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 14.67%. This liver cancer drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers liver cancer drugs market segmentation by:
Download the Free Report Sample to Unlock the Liver Cancer Drugs Market Size for the Forecast Period and Other Important Statistics
The liver cancer drugs market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc. among others.
The increasing incidence of liver cancer is notably driving the growth, although factors such as only curative option is surgical resection and transplantation may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the liver cancer drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Liver Cancer Drugs Market Driver
One of the key factors driving growth in the liver cancer drugs market is the increasing incidence of liver cancer. Liver cancer is among the leading causes of cancer-related deaths globally. The increase in the incidence of risk factors like hepatitis B and C and underlying cirrhosis will lead to the rise in the risk of liver cancer depends on the etiology. In the US, among patients with certain liver cancers in US, hepatitis C is present in more than half of this population. Around 15% of this group have hepatitis B. Every year, in the US, about 31,000 people get liver cancer. In the US, fatty liver is attributed as a major cause of liver cancer, which is followed by hepatitis C. Long-term alcohol consumption is also the primary reason for the increase in the incidence of liver cancer. Furthermore, the increase in the incidence of new risk factors like diabetes, obesity, and related non-alcoholic fatty liver disease may also be associated with the increase in the incidence of liver cancer.
Key Liver Cancer Drugs Market Trend
The use of mABs is a liver cancer drugs market trend that is expected to have a positive impact in the coming years. Mostly, liver cancer does not respond to chemotherapy, and monoclonal antibody therapies represent a new promising approach to treat liver cancer. The main challenge is the lack of understanding about tumor-specific targets. Research is being conducted to develop high-stability and high-affinity antibodies and fragments, which can target tumor-specific antigens in liver cancer. The main advantages of monoclonal antibodies are their sensitivity and their ability to create a level of specificity, which reduces the chances of deleterious side effects. Another advantage of using monoclonal antibodies for liver cancer is that they are highly stable. Currently, only one monoclonal antibody is approved to treat liver cancer. However, the pipeline has multiple monoclonal antibodies at different stages of evaluation.
Key Liver Cancer Drugs Market Challenge
The only curative option being surgical resection and transplantation will be a major challenge for the liver cancer drugs market during the forecast period. The treatment of liver cancer is decided by the stage of the disease and liver functioning. Disease-modifying drugs are neither available in the market nor in the pipeline to potentially cure liver cancer. Globally, consensus on the surgical treatment of liver cancer being a recommended option is yet to be obtained, which can be attributed to the variations in healthcare systems in different regions. Liver resection can be performed only in candidates who meet prerequisites for surgery. However, surgery is often associated with a high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation.
This liver cancer drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global liver cancer drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the liver cancer drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the liver cancer drugs market encompasses successful business strategies deployed by the key vendors. The liver cancer drugs market is fragmented and the vendors are deploying growth strategies such as acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share to compete in the market.
Bayer AG - The company offers drugs, treatment and diagnoses for liver cancer.
AstraZeneca Plc - The company offers Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
In order to make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The liver cancer drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the liver cancer drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
42% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for liver cancer drugs in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.
The development and launch of treatment therapies for liver cancer will facilitate the liver cancer drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 pandemic negatively impacted the region in 2020. Governments of the countries in the region imposed a nationwide lockdown, which limited the movement of people. In the first half of 2021, with the gradual decrease in the number of COVID-19 cases, lockdowns were lifted, leading to the reopening of healthcare facilities and clinics. Regular operations and checkups have also started up for cancer. This, in turn, will have a positive impact on the regional liver cancer drugs market and thus, we can see a high growth rate during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The liver cancer drugs market share growth by the immunotherapy segment will be significant during the forecast period. The market is expected to experience moderate growth during the forecast period. Immunotherapy is a specific treatment that uses the immune system of the body to fight cancer.
This report provides an accurate prediction of the contribution of all the segments to the growth of the liver cancer drugs market size and actionable market insights on post COVID-19 impact on each segment.
Liver Cancer Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.67% |
Market growth 2022-2026 |
$ 5.29 billion |
Market structure |
Fragmented |
YoY growth (%) |
10.4 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 42% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.